China's Nuance Biotech Options Two Cancer Treatments from Celleron

Nuance Biotech of Shanghai has acquired an option from Oxford's Celleron Therapeutics for rights to two Celleron clinical-stage cancer treatments in Greater China and South Africa. The two companies will conduct clinical trials of the Celleron assets in Oxford, China and South Africa. Nuance will make upfront, development and regulatory milestone payments to Celleron, and it will be responsible for all development and commercialization expenses in its territories. More details.... Share this with colleagues: // //